Industry Group Challenges CA Prop. 65 DEA Warning Requirement

Why It Matters

If successful, the lawsuit could reshape California’s warning regime, reducing compliance costs for cosmetics firms and setting a precedent for First‑Amendment challenges to environmental labeling.

Key Takeaways

• PCPC sues over DEA Prop 65 warning requirement
• Claims warning forces false, misleading message
• IARC classifies DEA as possible carcinogen, limited evidence
• Over 1,400 DEA warning notices filed since 2012

Pulse Analysis

California’s Proposition 65 has long required businesses to post clear warnings when products contain chemicals the state deems carcinogenic. Diethanolamine (DEA), a common ingredient in shampoos and lotions, was added to the list in 2012 after the International Agency for Research on Cancer (IARC) labeled it a possible human carcinogen (Group 2B). The Personal Care Products Council’s recent lawsuit contends that the warning is not only scientifically tenuous but also constitutionally problematic, alleging that it forces manufacturers to convey a misleading health risk to consumers.

The scientific foundation for DEA’s classification is narrow. IARC’s assessment relied primarily on a single mouse strain highly prone to tumors, while a parallel rat study found no carcinogenic effect and human data remain inconclusive. PCPC argues that this limited evidence does not satisfy the “clear and reasonable” standard required for Prop 65 warnings, and that the mandated label could erode consumer trust by overstating risk. The lawsuit follows a wave of First‑Amendment challenges targeting Prop 65 warnings for other contentious chemicals, highlighting a growing tension between state-level hazard communication and federal free‑speech protections.

For the cosmetics and personal‑care industry, the case carries significant financial and operational stakes. Companies have filed more than 1,400 DEA‑related notices, incurring labeling costs and facing potential penalties. A favorable ruling could prompt a reassessment of the state’s safe‑harbor levels and reduce the regulatory burden, while also influencing how other states approach chemical risk disclosures. Beyond California, the outcome may signal to regulators nationwide that robust scientific justification is essential before imposing mandatory health warnings, potentially reshaping the landscape of consumer‑product safety compliance.